Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024. These Stock Options will be under lockup for 46 days starting from 28-NOV-2023 to 13-JAN-2024.

Details:
In connection with this offering, company?s executive officers and directors have agreed with the Representative that, subject to certain customary exceptions, without the prior written consent of the Representative, for a period commencing on the date of the lock-up agreement and ending on the date that is the earlier of (i) forty-five days after the date of the lock-up agreement or (ii) the date on which the closing price of company?s common stock on the Nasdaq Capital Market is at or above 300% of the public offering price per share of common stock in this offering (subject to adjustments for stock dividends, stock splits, reverse stock splits, recapitalizations, reorganizations or other similar transactions), that they shall not (a) offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock , whether now owned or hereafter acquired by such executive officer or director or with respect to which the executive officer or director acquires the power of disposition (the ?Lock-Up Securities?), (b) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (a) or (b) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (c) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities; or (d) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities.